Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.

Registrati

Quotazioni in diretta

PHVS Pharvaris NV

18,84

-0,66 (-3,38%)

Ultimo aggiornamento: 20:25:47

Dati in Delay di 15 minuti

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

09/19/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Johannes Gerardus Christiaan Petrus Schikan

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Grafico Azioni Pharvaris NV (NASDAQ:PHVS)
Storico
Da Nov 2024 a Dic 2024

Clicca qui per i Grafici di Pharvaris NV

Grafico Azioni Pharvaris NV (NASDAQ:PHVS)
Storico
Da Dic 2023 a Dic 2024

Clicca qui per i Grafici di Pharvaris NV

Notizie Pharvaris NV - PHVS

Form 144 - Report of proposed sale of securities
Lunedì 2 Dicembre 2024 (4 settimane fa) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mercoledì 13 Novembre 2024 (1 mese fa) • Edgar (US Regulatory)

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Mercoledì 13 Novembre 2024 (1 mese fa) • GlobeNewswire Inc.

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
Martedì 12 Novembre 2024 (1 mese fa) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Giovedì 31 Ottobre 2024 (2 mesi fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Giovedì 24 Ottobre 2024 (2 mesi fa) • Edgar (US Regulatory)

Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
Giovedì 24 Ottobre 2024 (2 mesi fa) • GlobeNewswire Inc.

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
Mercoledì 16 Ottobre 2024 (2 mesi fa) • GlobeNewswire Inc.

Pharvaris to Host Virtual Investor Event on October 23, 2024
Martedì 15 Ottobre 2024 (2 mesi fa) • GlobeNewswire Inc.

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
Giovedì 3 Ottobre 2024 (3 mesi fa) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mercoledì 25 Settembre 2024 (3 mesi fa) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Lunedì 23 Settembre 2024 (3 mesi fa) • Edgar (US Regulatory)

Più Pharvaris NV Articoli Notizie

FluoroPharma Medical (CE)

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea